Immunologically Active Peptides From The HIV Envelope Protein Eliciting Both Antibody And T Cell Responses
Description of Invention:
This invention is a series of chemically synthesized peptides of about 15 amino acids in length from the gp160 envelope protein of various isolates of HIV-1. Antibodies raised against the peptides block proliferation of HIV and block HIV-induced cell fusion in cell culture. The peptides are potential vaccines against HIV infection and monoclonal antibodies raised against the peptides are potentially useful as therapeutics. Foreign equivalent cases to USSN 07/148,692 (Berzofsky et al., PCT/US89/00712) are also available for licensing.
The NIH has many other patents and pending patent applications, most foreign filed, claiming various peptides from the HIV envelope protein that are T helper epitopes, CTL epitopes and neutralizing antibody epitopes discovered in the laboratory of Dr. Jay Berzofsky. Dr. Berzofsky has designed synthetic chimeric peptides (called "multideterminant" peptides) that combine a peptide containing several T helper epitopes which can activate many human HLA types (called a "multicluster" peptide, and claimed in USSN 08/455,685) with a peptide combining a CTL and neutralizing B cell epitope (called a "p18" peptide, and claimed in USSN 07/847,311 and US patents 5,820,865 and 5,562,905). These multideterminant peptides contain only epitopes that lead to protection without containing epitopes that are detrimental to protection. Two of the multicluster chimeric peptides are in clinical trials. Multideterminant peptides are claimed in USSN 08/060,988 and 08/407,252.
Inventors:
William R. Kenealy Stephen R. Petteway Paul J. Durda
Patent Status:
DHHS Reference No. E-092-1988 --
U.S. Patent No. 5,562,905 issued 08 Oct 1996
For Additional Information Please Contact: Susan Ano Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301) 435-5515
Email: anos@mail.nih.gov
Fax: (301) 402-0220
